仁和药业股份有限公司 2021 年年度报告全文 仁和药业股份有限公司 2021 年年度报告 2022-017 2022 年 04 月 1 仁和药业股份有限公司 2021 年年度报告全文 积金转增股本。 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人杨潇、主管会计工作负责人彭秋林及会计机构负责人(会计主管 人员)朱凌云声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本年度报告涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者 的实质承诺，敬请投资者注意风险。 《证券日报》《证券时报》《中国证券报》和巨潮资讯网 www.cninfo.com.cn 为本公司 2021 年度选定的信息披露媒体，本公司所有信息均以在上述选定媒体 刊登的信息为准。同时，报告期内，不存在对公司生产经营产生实质性影响的 特别重大风险。公司已在本报告中阐述公司在生产经营过程中可能面临的各种 风险，请查阅第三节管理层讨论及分析中"可能面对的风险",敬 ...

仁和药业股份有限公司 2021 年第三季度报告 证券代码：000650 证券简称：仁和药业 公告编号：2021-059 仁和药业股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的 真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 √ 是 □ 否 追溯调整或重述原因 | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-----------------------------------------------------|-------------------|-------------------|-- ...

Financial Performance - The company's operating revenue for the first half of 2021 was ¥2,321,549,671.82, representing a 19.18% increase compared to ¥1,947,950,428.22 in the same period last year[26]. - The net profit attributable to shareholders of the listed company was ¥328,612,526.45, a 35.71% increase from ¥242,151,328.86 year-on-year[26]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥322,839,215.33, up 35.56% from ¥238,146,130.35 in the previous year[26]. - The basic earnings per share increased by 20.05% to ¥0.2347 from ¥0.1955 in the same period last year[26]. - The company achieved total revenue of CNY 2.32 billion in the first half of 2021, representing a year-on-year growth of 19.18%[54]. - Net profit attributable to the parent company reached CNY 329 million, an increase of 35.71% compared to the same period last year[54]. - The company's R&D investment increased by 29.02% to CNY 28.71 million, focusing on new product development and technological advancements[55]. Assets and Liabilities - The total assets at the end of the reporting period were ¥6,452,817,156.70, a 2.34% increase from ¥6,305,052,157.97 at the end of the previous year[26]. - The net assets attributable to shareholders of the listed company were ¥5,121,520,973.45, reflecting a 0.96% increase from ¥5,072,896,093.80 at the end of the previous year[26]. - The company's cash and cash equivalents decreased by 11.70% to ¥993,025,282.78, primarily due to cash dividends and significant business expenditures[65]. - Total current liabilities increased to ¥725,025,454.20 from ¥684,708,824.49, representing a growth of approximately 5.5%[198]. - Total liabilities reached ¥734,561,673.23, up from ¥694,536,400.03, reflecting a growth of around 5.8%[198]. Cash Flow - The net cash flow from operating activities was ¥181,988,972.64, down 21.15% from ¥230,803,810.41 in the same period last year[26]. - Operating cash flow decreased by 21.15% to CNY 181.99 million, primarily due to earlier cash expense settlements compared to the previous year[55]. - The company reported a significant decline in net cash flow from investment activities, down 178.46% to -CNY 557.13 million, attributed to multiple large certificate of deposit transactions[55]. Product Development and Market Focus - The company has a significant focus on new product development, technology improvements, and market expansion, with funding sourced from self-owned funds, raised capital, and cash flow from operations[40]. - The company reported a significant increase in revenue from its respiratory system products, particularly the compound paracetamol and phenylephrine capsules, which are used for treating cold and flu symptoms[43]. - The company is actively involved in the development of antiviral medications, such as Entecavir tablets, for the treatment of chronic hepatitis B, targeting both adult and pediatric populations[47]. - The company is exploring market expansion opportunities, particularly in the field of diabetes medications, with the introduction of Glimepiride sustained-release tablets for type 2 diabetes management[47]. Corporate Governance and Compliance - The company emphasizes that forward-looking statements do not constitute substantive commitments to investors, highlighting the importance of risk awareness[6]. - The company has not reported any discrepancies between financial reports prepared under international accounting standards and those under Chinese accounting standards[28]. - The company has committed to timely and complete execution of measures related to compensation for dilution of immediate returns[116]. - The company has established measures to ensure independence in operations, assets, and finances from its controlling shareholder[130]. Environmental and Social Responsibility - The company is actively involved in poverty alleviation efforts, including skills training and project development[109]. - The company has established emergency response plans for hazardous chemicals and environmental incidents, conducting multiple drills[107]. - The company has not reported any major environmental issues or pollution incidents, adhering strictly to national environmental standards[108]. Shareholder Information - The annual shareholders' meeting had a participation rate of 37.42% on May 17, 2021[91]. - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[96]. - The largest shareholder, Renhe (Group) Development Co., Ltd., holds 23.24% of the shares, totaling 325,299,386 shares[167].

证券代码：000650 证券简称：仁和药业 公告编号：2021-020 仁和药业股份有限公司 关于参加 2021 年投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为便于广大投资者更深入全面地了解公司情况、发展战略、经营状况、融资 计划、股权激励和可持续发展等投资者所关心的问题，公司定于2021年5月14日 下午参加由江西省上市公司协会联合深圳市全景网络有限公司举办的主题为"心 系投资者 携手高质量发展"江西上市公司2021年投资者集体接待日活动。现将 有关事项公告如下： 网上交流时间：2021年5月14日（周五）下午15:00-17:00 本次集体接待日网上交流网址：投资者可以登录http://rs.p5w.net进入专 区页面参与交流。 出席本次集体接待日的人员有：公司董事长、财务总监、董事会秘书。欢迎 广大投资者积极参与。 特此公告 | --- | --- | --- | --- | |-------|-------|-------|----------------------| | | | | 仁和药业股份有限公司 | ...

仁和药业股份有限公司 2021 年第一季度报告全文 仁和药业股份有限公司 2021 年第一季度报告 2021-019 2021 年 04 月 1 仁和药业股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人梅强、主管会计工作负责人彭秋林及会计机构负责人(会计主管 人员)肖雪峰声明：保证季度报告中财务报表的真实、准确、完整。 2 仁和药业股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|---------------------------| | □ 是 √ 否 | 本报告期 ...

Financial Performance - The company reported a total revenue of 1.4 billion RMB for the year 2020, marking a year-on-year increase of 10%[17] - The net profit attributable to shareholders was 200 million RMB, representing a growth of 15% compared to the previous year[17] - The company's operating revenue for 2020 was ¥4,106,104,187.58, a decrease of 10.37% compared to 2019[25] - The net profit attributable to shareholders for 2020 was ¥568,711,144.74, an increase of 5.74% from the previous year[25] - The total profit for the year was 848 million yuan, with a net profit of 658 million yuan, and the net profit attributable to the parent company was 569 million yuan, representing a growth of 5.74% compared to the previous year[55] - The company reported a quarterly revenue of ¥1,148,139,743.99 in Q4 2020, showing a strong performance in the last quarter[31] - The net cash flow from operating activities increased by 25.53% to ¥871,131,642.15 in 2020[25] - The total assets of the company increased to 3 billion RMB, reflecting a growth of 8% from the previous year[17] - Total assets at the end of 2020 reached ¥6,305,052,157.97, reflecting a growth of 26.50% compared to the end of 2019[28] - The net assets attributable to shareholders increased by 33.30% to ¥5,072,896,093.80 at the end of 2020[28] Market Strategy and Expansion - The company is focusing on expanding its market presence in Southeast Asia, targeting a 20% market share in the region by 2023[17] - The company anticipates a revenue growth of 12% for 2021, driven by new product launches and market expansion strategies[17] - The company has established a sales network covering 30 provinces and regions in China, enhancing its market presence[47] - The company is positioned to benefit from the expiration of patents on major drugs globally, presenting substantial growth opportunities[46] Product Development and Innovation - New product development efforts led to the launch of 10 new pharmaceutical products in 2020, contributing to 30% of total sales[17] - The company plans to focus on new product development, technological advancements, and market expansion, with funding sourced from self-owned funds and cash flow from operations[46] - The company emphasizes the importance of innovation and new product development as a key driver for sustainable growth in the health sector[151] - The company aims to enhance its market presence through the development of new products and technologies[95] Research and Development - The company has invested 100 million RMB in R&D for new technologies aimed at improving production efficiency[17] - Research and development expenses for 2020 were ¥39,794,065.76, an increase of 4.61% compared to 2019[93] - The company has increased its investment in research and development, focusing on technological upgrades and new product development[61] - The company’s R&D capitalization rate significantly decreased to 1.07% from 12.75% due to ongoing development projects[109] Regulatory Environment and Risks - The company faces risks from industry policy adjustments, as the pharmaceutical industry is highly regulated, and changes in drug bidding policies can significantly impact market sales[55] - The company reported a risk of price reductions due to government regulation on drug prices, with a trend of lower bidding prices expected in the procurement process[56] - The pharmaceutical industry in China is undergoing significant reforms aimed at addressing supply-demand imbalances, particularly in high-end and generic drug markets[43] Corporate Governance and Compliance - The company is committed to maintaining compliance with regulations while adapting to the evolving market landscape[55] - The company has a comprehensive quality control system in place, adhering to national regulations and certifications such as GSP and GMP to mitigate drug safety risks[56] - The company has not experienced any major litigation or arbitration matters during the reporting period[191] - There are no penalties or rectification situations reported for the company during the reporting period[193] Financial Management and Investments - The company reported a significant increase in financing cash flow net amount by 467.58% to ¥617,601,241.73, primarily due to a targeted stock issuance[110] - The total amount of raised funds was CNY 82,288,910, with CNY 10,241,450 utilized so far, leaving CNY 72,150,670 unutilized[130] - The company has not made any significant changes to its asset measurement attributes during the reporting period[119] - The company utilized RMB 450,000,000.00 of idle raised funds for cash management, with the remaining RMB 271,506,667.26 kept in demand deposits[137] Dividend Policy - The company plans to distribute a cash dividend of 2 RMB per 10 shares, based on a total of 1,399,938,234 shares[8] - The cash dividend for 2020 represented 49.23% of the net profit attributable to shareholders, maintaining a consistent dividend policy over the past three years[170] - The company plans to distribute a cash dividend of 2.00 CNY per 10 shares, totaling 279,987,646.80 CNY, which represents 100% of the distributable profit[171] Subsidiaries and Related Transactions - The company established two new subsidiaries during the reporting period, enhancing its operational scope[85] - The company has included two new subsidiaries in the consolidated financial statements: Jiangxi Renhe Logistics Co., Ltd. and Jiangxi Herun Information Consulting Co., Ltd. due to their establishment[186] - The company engaged in related party transactions, including purchasing goods from Hainan Sanpu Biotechnology Co., Ltd. for 226,649.11 RMB, accounting for 22.66% of similar transactions[197] Industry Outlook - The pharmaceutical industry is expected to experience significant growth opportunities due to favorable government policies and reforms[41] - China's aging population is projected to reach one-third of the total population by 2050, significantly increasing the demand for medication[42] - The Chinese pharmaceutical market is expected to reach a total output value of 10 trillion yuan, ranking second globally[46]

仁和药业股份有限公司 2020 年第三季度报告全文 仁和药业股份有限公司 2020 年第三季度报告 2020-048 2020 年 10 月 1 仁和药业股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人梅强、主管会计工作负责人彭秋林及会计机构负责人(会计主管 人员)肖雪峰声明：保证季度报告中财务报表的真实、准确、完整。 2 仁和药业股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |-----------------------------------------------------|-------------------------------|-------------------------|------------------|-- ...

仁和药业股份有限公司 2020 年半年度报告全文 仁和药业股份有限公司 2020 年半年度报告 2020-044 2020 年 08 月 1 仁和药业股份有限公司 2020 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人梅强、主管会计工作负责人彭秋林及会计机构负责人(会计主管 人员)肖雪峰声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本半年度报告涉及的未来计划、发展战略等前瞻性描述不构成公司对投资 者的实质承诺，敬请投资者注意风险。 《证券日报》《证券时报》《中国证券报》和巨潮资讯网 www.cninfo.com.cn 为本公司 2020 年半年度选定的信息披露媒体，本公司所有信息均以在上述选定 媒体刊登的信息为准。同时，报告期内，不存在对公司生产经营产生实质性影 响的特别重大风险。公司已在本报告中阐述公司在生产经营过程中可能面临的 各种风险，请查阅第四节经营情况讨论与分析中"十、公司面临的风险 ...

证券代码：000650 证券简称：仁和药业 公告编号：2020-028 仁和药业股份有限公司 关于参加 2020 年投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 为便于广大投资者更深入全面地了解公司情况、发展战略、经营状况、融资 计划、股权激励和可持续发展等投资者所关心的问题，公司定于2020年7月17日 下午参加由江西省上市公司协会联合深圳市全景网络有限公司举办的主题为"以 高质量沟通 促高质量发展"江西上市公司2020年投资者集体接待日活动。现将 有关事项公告如下： 网上交流时间：2020年7月17日（周五）下午15:00-17:00 本次集体接待日网上交流网址：投资者可以登录http://rs.p5w.net进入专 区页面参与交流。 出席本次集体接待日的人员有：公司董事长、财务总监、董事会秘书。欢迎 广大投资者积极参与。 特此公告 | --- | --- | --- | --- | |-------|-------|-------|----------------------| | | | | 仁和药业股份有限公司 | ...

Financial Performance - The company's operating revenue for Q1 2020 was ¥881,907,797.30, a decrease of 25.89% compared to ¥1,190,024,065.86 in the same period last year[10] - Net profit attributable to shareholders was ¥103,207,337.83, down 27.73% from ¥142,799,371.77 year-on-year[10] - Basic and diluted earnings per share were both ¥0.08, representing a decrease of 33.33% from ¥0.12 in the same period last year[10] - The net profit attributable to the parent company decreased by 27.73% to 103,207,337.83, impacted by reduced operating profit due to the pandemic[26] - The total operating income for the current period is CNY 11,762,834.93, a decrease from CNY 12,520,520.39 in the previous period, representing a decline of approximately 6.06%[77] - The net profit for the current period is CNY 115,998,784.14, compared to CNY 165,206,534.29 in the previous period, reflecting a decrease of approximately 29.67%[72] - The total profit for the current period is CNY 147,918,996.44, down from CNY 212,218,788.50, indicating a decline of approximately 30.29%[72] - The total comprehensive income attributable to the parent company's owners is CNY 103,207,337.83, down from CNY 142,799,371.77, a decrease of approximately 27.73%[76] Cash Flow - The net cash flow from operating activities was -¥32,536,765.31, a significant decline of 945.34% compared to ¥3,848,955.99 in the previous year[10] - Cash inflow from operating activities totaled 1,324,703,540.70 yuan, an increase from 1,030,455,484.15 yuan in the previous period[84] - The cash inflow from investment activities was 2,925,376,891.52 yuan, compared to 2,583,425,372.39 yuan in the previous period[87] - The cash outflow from investment activities totaled 2,192,402,116.55 yuan, a decrease from 2,606,060,959.79 yuan in the previous period[87] - The net increase in cash and cash equivalents was 700,438,009.66 yuan, compared to a decrease of 20,654,028.26 yuan in the previous period[90] - The company's cash and cash equivalents increased to 2,119,677,581.42 CNY as of March 31, 2020, compared to 1,419,239,571.76 CNY at the end of 2019, reflecting a growth of approximately 49.3%[50] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,125,804,276.23, an increase of 2.84% from ¥4,984,426,490.50 at the end of the previous year[10] - The total liabilities increased to CNY 1,051,941,522.17 from CNY 752,836,765.65, reflecting a growth of approximately 39.8%[66] - The total equity attributable to shareholders reached CNY 2,424,871,688.79, slightly up from CNY 2,419,864,660.21, showing a marginal increase of about 0.2%[66] - The total non-current liabilities amounted to CNY 10,852,279.57, up from CNY 9,326,146.19, reflecting an increase of about 16.4%[59] - The company's total equity increased to CNY 4,467,956,625.05 from CNY 4,351,956,409.61, representing a growth of approximately 2.7%[59] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 149,019[14] - The company's retained earnings rose to CNY 522,174,303.75 from CNY 517,167,275.17, indicating a growth of about 1.4%[66] Operational Changes - Accounts receivable increased by 81.22% as the sales model shifted to terminal cooperative clients, leading to increased credit sales[26] - Prepayments rose by 33.94% primarily due to increased material purchases during the period[26] - Other receivables increased by 91.15% due to pre-allocated marketing promotion expenses[26] - Construction in progress increased by 50.88% due to investments in high-quality pharmaceutical projects[26] - The company did not acquire any new subsidiaries during the period, resulting in a 100% decrease in cash paid for acquiring subsidiaries[29] Government and Other Income - The company received government subsidies amounting to ¥1,009,612.72 during the reporting period[10] - Other income decreased by 72.74% due to a significant project reward received in the same period last year[26] Financial Management - Financial expenses decreased by 42.6% due to higher interest income compared to the same period last year[26] - The company has no derivative investments during the reporting period, indicating a conservative investment strategy[46] - There were no violations regarding external guarantees or non-operating fund occupation by controlling shareholders during the reporting period[44][45] Accounting Standards - The new revenue and lease standards were first implemented in 2020, with retrospective adjustments made to prior comparative data[97] - The company has not audited its first quarter report[97]